A phase 1 study of durvalumab as monotherapy or combined with tremelimumab with or without azacitidine in patients with myelodysplastic syndrome

By sjmartinez • March 29, 2025

Garcia-Manero G, Gaddh M, Platzbecker U, Lindsley RC, Larson SM, Chevassut T, Fenaux P, Komrokji R, Lyons R, Al-Kali A, Jiang Y, Bothos J, Townsley DM, Zeidan AM. A phase 1 study of durvalumab as monotherapy or combined with tremelimumab with or without azacitidine in patients with myelodysplastic syndrome. Ann Hematol. 2025 Mar 28. doi: 10.1007/s00277-024-06081-4. Epub ahead of print. PMID: 40153010.

Tags: Acute myeloid leukemia, CTLA-4, durvalumab, First-in-human, Hematology/Oncology, MDS, PD-L1, Publications

Somatic Tumor Next-Generation Sequencing in US Veterans With Metastatic Prostate Cancer

Valle LF, Li J, Desai H, Hausler R, Haroldsen C, Chatwal M, Ojo M, Kelley MJ, Rebbeck TR, Rose BS, Rettig MB, Nickols NG, Garraway[...]

Expert consensus on treating HR+/HER2- metastatic breast cancer based on real-world practice patterns observed in the RETRACT survey of US oncologists

Rugo HS, Bardia A, Gradishar WJ, Hamilton EP, Hurvitz SA, Jhaveri K, Mahtani R, Tolaney SM. Expert consensus on treating HR+/HER2- metastatic breast cancer based[...]

Brief Report: The Genomic Landscape of Small Cell Lung Cancer in Never-Smoking Patients

Oh MS, Garon EB, Lisberg AE, Cummings AL, Barrett A, Ashok A, Mauer E, Yilma B, Goldman JW. Brief Report: The Genomic Landscape of Small[...]